Regulatory & Reimbursement
FDA Output, April 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in April 2026. Updated April 16.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
The Digest
The Digest: April 2026
In this month's news, mixed results for clinical trials, Merit Medical continues its buying streak with View Point Medical, six FDA clearances, and more.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
ICYMI
Low Back Pain Treatment Gets Personal
The treatment of low back pain is beginning to move toward a more stratified, personalized model of care. Scientific and technological advances are creating opportunities for new entrants in the market. Excerpted from our recent feature article.